Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 6/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482256 | 1.00 | GAA (0.37) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL29986851 | 1.00 | GAA (0.37) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL14345814 | 1.00 | GAA (0.37) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL5651723 | 0.96 | SRC (0.40) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL15365458 | 0.96 | AR (0.39) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL5651729 | 0.96 | SRC (0.40) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL15365315 | 0.96 | AR (0.39) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL15365401 | 0.96 | AR (0.39) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL15365246 | 0.96 | AR (0.39) | GAAARMAPTEGFRERBB2 | |
| SCHEMBL29577679 | 0.86 | MAOB (0.39) | GAAMAPTMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411373-B1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LAB LTD (IN) | 2015-10-21 | — | — | EP | disclosed |
| EP-2139868-B1 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LTD (IN) | 2015-07-29 | — | — | EP | disclosed |
| US-20140194624-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | CIPLA LIMITED (IN) | 2014-07-10 | — | — | US | disclosed |
| US-8642758-B2 | Process for preparation of erlotinib and its pharmaceutically acceptable salts | CIPLA LIMITED (IN) | 2014-02-04 | — | — | US | disclosed |
| US-8440823-B2 | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof | RANBAXY LABORATORIES LIMITED (IN) | 2013-05-14 | — | — | US | disclosed |
| US-20120101272-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2012-04-26 | — | — | US | disclosed |
| EP-2411373-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Ranbaxy Laboratories Limited (IN) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109443-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-30 | — | — | WO | disclosed |
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | CIPLA LIMITED (IN) | 2010-04-15 | — | — | US | disclosed |
| EP-2139868-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Cipla Limited (IN) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122776-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LIMITED (IN) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101272-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRAS, EGFR, CSNK1E | GAA 1159/4885AR 3748/4885MAPT 1508/4885 |
| US-20140194624-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | ABL1, EGFR, KRAS | GAA 1351/4885AR 3288/4885MAPT 2629/4885 |
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | ABL1, EGFR, KRAS | GAA 1060/4885AR 2615/4885MAPT 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.